Summary: P-Selectin represents a cell surface glycoprotein that is constitutively present in the Weibel-Palade bodies of endothelial cells and in the &alpha;-granules of platelets. In inflammation and thrombogenic conditions, plasmatic P-selectin levels are markedly elevated, indicating the leakage of this marker from these sites. In this study, a quantitative sandwich enzymelinked immunosorbent assay (ELISA) utilizing a monoclonal soluble P-selectin (sP-selectin) antibody was employed to assess this marker in blood samples collected in various anticoagulants such as heparin, hirudin, sodium citrate (3.2% and 3.8%), and ethylenediaminetetraacetic acid (EDTA). The soluble P-selectin levels ranged from 26 ng/mL to 44 ng/mL. Sodium citrate (3.8%) was used to collect platelet-poor plasma (PPP) from patients with heparin-induced thrombocytopenia (HIT), coronary angioplasty (CA), or coronary atherectomy (CAT) . In comparison with the control group (&sim; 30 ng/mL), all of these patient groups showed a marked elevation of sPselectin levels (HIT = 96 ng/mL [n = 18] , CA = 46 ng/mL [n = 6] and CAT = 60 ng/mL [n = 10] ). In platelet-rich plasma (PRP) preparations using various anticoagulants, the sP-selectin levels were markedly higher, ranging from 87 ng/ mL to 117 ng/mL (n = 10). In patients recruited into a clinical trial (the argatroban [ARG] 911 Study), in which argatroban was used as an alternate anticoagulant in patients with HIT, a 25% to 35% decrease in sP-selectin levels was observed after 72 hours of argatroban treatment. In addition, the relative ratio between levels in PRP and PPP in these patients differed, suggesting that the anticoagulant matrix influences the sP-selectin levels. These (2) . Cell-surface expression of P-selectin, however, lasts only for a few minutes. Surface translocation of P-selectin is essential for its involvement in the adhesion of myeloid and lymphoid cells to endothelium (3) . Such adhesion is initiated by a characteristic rolling motion of the leukocytes and neutrophils on the endothelial surface (4) . In addition, translocated P-selectin mediates the adhesion of platelets to monocytes and neutrophils during thrombus formation. Several thrombotic and inflammatory agents are implicated in the activation of platelets and endothelial cells, with the subsequent surface expression of P-selectin. Thrombin, histamine, complement molecules, oxygen-free radicals, and cytokines are among these agents (1, 5) .
Three different forms of P-selectin have been identified. The finding that one of these forms lacks the transmembrane domain (6) predicted the presence of a soluble isoform. Recent studies (7) (8) (9) have indeed shown that a functionally active, soluble form of P-selectin (sPselectin) is present in the serum. Controversy has surrounded the source of sP-selectin. Although some reports demonstrate that sP-selectin arises from the platelets (10, 11) , others support an endothelial origin (12) . Increased levels of sP-selectin have been demonstrated in a variety of clinicopathologic disorders, including thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, disseminated intravascular coagulation, systemic lupus erythromatosus, rheumatoid arthritis, diabetes mellitus, atherosclerosis, angina, acute myocardial infarction, and congestive heart failure, and also after heart transplantation (10, (12) (13) (14) (15) (16) (17) (18) (19) (20) Figure 1 . No significant differences were detected among the different anticoagulants. Figure 2 illustrates the sP-selectin levels in PRP collected in different anticoagulants. sP EDTA plasma. No significant differences, however, were detected among the five anticoagulants used in the study. Figure 4 shows the significantly increased levels of sP-selectin in plasma obtained from various patient groups, as compared with the normal controls (33 ± 13 ng/mL). The different increased levels of sP-selectins in patients were as follows: HIT (96 ± 12 ng/mL), CA (51 1 ± 12 ng/mL), and CAT (63 ± 14 ng/mL), which were significantly higher (p < 0.05). Figure 5 shows a comparison of of the soluble P-selectin levels in normal plasma and plasmas from patients under treatment for HIT at pretreatment, and at 24 hours and 72 hours during argatroban-treatment periods. The normal P-selectin levels were 32 ± 7 ng/mL, whereas a markedly higher P-selectin level was determined for the HIT patients (98 ± 10 ng/mL). At the P-selectin level decreased to 79 ± 8 ng/mL, and with 72 hours of treatment, the levels were 68 ± 6 ng/mL. These data indicate that in comparison to normal control subjects, the group of patients with HIT exhibited a 1.5-to 3-fold higher level of soluble P-selectin, which was statistically significant in comparison with normal controls (p < 0.05).
DISCUSSION
The interaction of different adhesive molecules with endothelium, platelets, and leukocytes has been implicated in several physiologic and pathologic situations (23, 24) . Selectins, including P-, E-, and L-selectin, constitute a distinct family of these adhesive molecules. Pselectin exists in three different forms, of which a soluble form (sP-selectin) is present as a circulating molecule in the plasma. sP-Selectin was found to be increased in a number of clinicopathologic conditions. Cardiovascular diseases, platelet function defects, and thrombotic abnormalities are among the most important disorders on this list (12, 13, 15, (18) (19) (20) . The exact role of sP-selectin in these pathologic conditions has not yet been elucidated fully. Contrary to the membrane-bound forms of Pselectin, sP-selectin might produce a protective effect by limiting the inflammatory reactions (25) .
Assays of platelet factor 4, r3-thromboglobulin, and prostacyclin are among the most reliable methods for the detection of platelet and endothelial cell activation. However, technical limitations pertaining to sample collection, processing, and analysis hinder the widespread utilization of these assays in clinical practice. Flow cytometric analysis of circulating activated platelets using fluorescein-labeled antibodies which react with platelet glycoprotein IIb/IIIa or surface P-selectin is limited by the rapid removal of activated platelets from the circu-lation. Recently, sP-selectin has emerged as a potential marker to monitor platelet and endothelial cell activation (26, 27) . Hence, optimization of the methods used to collect and process blood samples for the measurement of sP-selectin concentration appears to be necessary. In the present work, we utilized a sandwich enzyme-based immunoassay (ELISA) to measure sP-selectin concentrations in platelet-poor plasma (PPP), platelet-rich plasma (PRP), and serum samples obtained from healthy human volunteers. The PPP and PRP samples were collected into five different, commercially available anticoagulants. In addition, we measured the plasmatic levels of sP-selectin in patients with heparin-induced thrombocytopenia (HIT) and in patients who underwent coronary angioplasty (CA) or coronary atherectomy (CAT) as well.
The present study illustrates that the anticoagulant matrix has no significant effect on the concentration of sPselectin in PPP. Similar findings previously were obtained with citrate and EDTA (12) . In (29) .
Heparin is a mixture of negatively charged glycosaminoglycans that could be expected to induce Ca2+ chelation with a subsequent increase in sP-selectin levels in PRP. However, the binding of heparin to platelet factor 4 (a highly positively charged chemokine) appears to neutralize the negative charges and reduce or eliminate Ca2+ chelation. A previous report showed that heparininduced platelet activation and expression of P-selectin was dose dependent (28) . Indeed, higher doses of heparin led to more expression of P-selectin on activated platelets (28) . In our study, sP-selectin levels in PRP collected by using heparin at a concentration of 10 ¡J-g/mL were lower than sP-selectin levels in PRP collected with Ca2+-chelating anticoagulants. Hirudin Previous studies have shown a significant increase in sP selectin occurs in platelet functional defects, such as thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (12, 13, 15) . The present study demonstrated a significant increase in sP-selectin concentration in HIT patients, which is consistent with previous findings (12 (22) .
CONCLUSIONS
In conclusion, sP-selectin is a reliable marker for monitoring platelet activation and endothelial perturbation. Our study showed that the levels of sP-selectin in patients with HIT and also in patients with cardiovascular disorders who underwent CA and CAT procedures were significantly increased, compared with normal, healthy control subjects. The sandwich enzyme immunoassay utilized in the present study is a fast, accurate, and reliable method for the determination of sP-selectin concentrations. In addition, the anticoagulant matrix has no apparent effect on the levels of sP-selectin measured in PPP. Platelets, however, should be rigorously separated from plasma samples to avoid a spurious increase in sP-selectin levels. Because of the potential effect of Ca2+-chelating anticoagulants on inducing platelet activation, the utilization of hirudin or a small concentration of heparin as an anticoagulant is recommended.
